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Abstract
The aim of this paper was to evaluate the activity and tolerability of oral vinorelbine in patients with advanced castration resistant
prostate cancer (CRPC) who progressed after a minimum of three lines including: abiraterone acetate, docetaxel, cabazitaxel, and
enzalutamide.
Treatment consisted of weekly oral vinorelbine 60mg/m2. Chemotherapy was administered until disease progression or
unacceptable toxicity.
Twenty-six patients received vinorelbine: their median age was 74 years (range 58–84 years). Twenty-four (92.3%) patients had
bonemetastases. A decrease in PSA levels ≥50%was observed in 2 patients (7.7%). Among the subjects who were symptomatic at
baseline, pain was reduced in 3 patients (13.6%) with a significant decrease in analgesic use. Median progression-free survival was 9
weeks (95% CI: 7 to 11) and median overall survival was 17 weeks (95% CI: 12 to 22). Treatment was well tolerated, and no grade 4
toxicities were observed.
Our findings do not suggest the use of oral vinorelbine on a weekly schedule, in CRPC heavily pre-treated.
Abbreviations: CRPC= castration resistant prostate cancer, OS= overall survival, PCWG2= Prostate Cancer Working Group 2,
PFS = progression-free survival, PSA = prostate specific antigen.
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Prostate cancer is the most common cancer among occidental
men.[1] Castration resistant prostate cancer (CRPC) is defines as
the progression of disease after or during medical and/or surgical
castration. In the setting of CRPC, several new agents withEditor: Jianxun Ding.
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1different mechanisms of action have been approved;[2] these
include older or novel taxanes, novel oral anti-androgen drugs
such as enzalutamide or abiraterone acetate, immunotherapy
(sipuleucel-T) and bone targeted agent (radium-223).[2] All these
drugs have shown to improve survival; however, most patients
will progress developing resistance, underlying amedical need for
this subgroup of patients. In this setting, various alternative
options for heavily pre-treated patients have been proposed
including: estramustine phosphate, docetaxel rechallenge and
carboplatin plus etoposide, which were based on small clinical.[3–
5]
Among other chemotherapeutic agents, Vinorelbine, a semi-
synthetic vinca alkaloid that is a mitotic inhibitor with better
therapeutic index and lower neurotoxicity with respect to other
vinca alkaloids has showed certain efficacy and safety in the
treatment of patients withmetastatic CRPC,[6–7] in particular, the
oral administration of vinorelbine that is an easy route of
administration compared with intravenous, achieved results and
good safety profile also in elderly patients,[8] which are ideally
comparable to an heavily pre-treated population of patients.
Based on these studies, we performed a phase II study to
evaluate efficacy and safety of oral vinorelbine in patients with
advanced CRPC who have been heavily pre-treated.
2. Materials and methods
2.1. Inclusion criteria
Patients were enrolled if had a histologically confirmedmetastatic
CRPC. Patients must progress after previous lines of therapies
including abiraterone acetate, docetaxel, cabazitaxel, and
enzalutamide (with a minimum of 3 lines of therapies for
patient), as defined by Prostate Cancer Working Group 2
(PCWG2) criteria.[9,10]
Table 1
Patient characteristics.
Enrolled patients 26
Median age (range): years 74 (58-84)
Previous treatment
Prostatectomy 19
Radiotherapy 13
Number of prior lines for CRPC
3 26
>3 14
Previous therapies for CRPC
Docetaxel 26
Abiraterone acetate 26
Enzalutamide 18
Cabazitaxel 9
Other 13
Laboratory: median serum value, range
PSA, ng/mL 140 (0.8–9820)
Hemoglobin, g/dL 10.6 (9.0–12.4)
LDH, U/L 225 (90–1980)
Sites of metastases
Bone 24
Lymph nodes 14
Lung/liver 6
Pain present 22
Requiring opiates 15
ECOG performance status
0 5
1 16
2 5
Gleason Grade
<8 13
≥8 13
Table 2
Outcomes summary.
Enrolled patients 26
Median duration of treatment (weeks) 7
PSA decline (%)
≥30% 5 (19.2)
≥50% 2 (7.7)
Survival
PFS, median (weeks; 95% CI) 9 (7–11)
OS, median (weeks; 95% CI) 17 (12–22)
Palliative response (%) 3 (13.6)
Median duration of palliative response (weeks; 95% CI) 7 (3–10)
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agonists during CRPC status of disease. All patients had Eastern
Cooperative Oncology Group performance status of2, hepatic,
renal adequate and hematological function. The exclusion
criteria were other previous malignant disease and other clinically
significant disease with a special attention with cardiovascular.
All patients gave their informed consent and the protocol was
approved by local Ethics Committee.
2.2. Treatment plan and assessments
Treatment consisted of weekly oral vinorelbine 60mg/m2. Cycles
were administered if patients had adequate renal (serum creatinine
2.0mg/dL), hepatic function (serum bilirubin 2.0mg/dL) and
hematological (leukocytes ≥3000/mm3; hemoglobin ≥10g/dL,
platelets ≥100,000/mm3). Patients continued to take analgesic
medications toprovideoptimal pain control.All patientswithbone
metastases received bone-targeted agent if clinically indicated.
Vinorelbine was administered until disease progression or
unacceptable toxicity. An antiemetic pre-medication with ondan-
setron 8mg per os was administered if clinically indicated.
After the first occurrence of a grade III haematologic toxicity
the treatment was delayed and administered at the same dose
after complete recovery. If there was grade IV toxicity, the
treatment was interrupted, and after a maximum of 3 weeks
for recovery, the patients restarted subsequent administrations to
30mg. If there was another episode of grade IV toxicity, the
treatment was interrupted. Anamnestic and physical evaluation
was performed at baseline in all patients. Every 3 weeks, we
performed blood tests including prostate specific antigen (PSA)
and every 2 months we performed radiological assessments,
including computed tomography scans of the thorax, abdomen,
and pelvis. Follow-up data were available for all patients.
2.3. Outcome measures
PSA response was defined by ≥50% decline from baseline, while
a ≥25% PSA increase, confirmed with a second PSA reading after
a minimum of 3 weeks, was used to determine PSA progression
and response duration. RECIST 1.1 criteria were used to assess
measurable disease.[11] Median overall survival (OS) was
measured from the start of vinorelbine to death or censoring.
Kaplan–Meier estimates by the STATA/IC version 12 software
were used to determine progression-free survival (PFS), defined as
time from start of chemotherapy to time of PSA progression,
symptomatic progression and/or radiographic progression.
Pain symptomatology was measured at baseline and then every
3 weeks by the McGill Melzack Pain Questionnaire.[12] National
Cancer Institute Common Terminology Criteria for adverse
events (version 3.0 were adopted to grade the adverse events[13]).
2.4. Statistical analysis
PSA response was the primary endpoint. In accordance with
Simon minimax design a sample size of 25 patients was planned,
assuming a response rate of approximately 10% for other fourth-
line chemotherapies, and a target level of interest of 30%, with an
a of 0.05 and a b of 0.90. Overall survival, PFS, and pain
response were secondary endpoints.
3. Results
FromMarch 2016 to December 2017, a total of 26 patients were
enrolled. Table 1 reported the baseline and clinical characteristics2of the included patients. Their median age was 74 years (range
58–84 years). Bone metastases were present in 24 (92.3%) men.
Median PSA level at baseline was 140ng/mL (range 0.8–9820ng/
mL). All patients were treated with almost three lines of therapies
for CRPC, all patients performed prior docetaxel and abiraterone
acetate while 18 and 9 patients were treated with prior
enzalutamide and cabazitaxel respectively.
Median duration of treatment with vinorelbine was 7 weeks. A
decrease in PSA levels ≥30% was observed in 5 patients (19.2%)
(Table 2). Out of the 9 patients previously exposed to cabazitaxel,
one (11.1%) achieved a PSA response. In the subgroup of
patients who received previous enzalutamide, 4 (22.2%) out of
18 patients achieved a PSA response.
After a median follow-up of 13 weeks, the median PFS was
9 weeks (95% CI: 7 to 11) and median OS was 17 weeks (95%
Figure 1. PFS and OS of the 26 enrolled patients.
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the role of basal values of PSA, we found that men with values of
PSA higher than median (140ng/mL) had a shorter PFS if
compared with men with lower PSA values (6 vs 9 weeks; P= .1),
additionally OS was further shorter in men with higher values of
PSA (13 vs 15 weeks, P= .4), however although a trend has been
observed suggesting that basal values of PSA is prognostic and
predictive of efficacy, the absence of a statistical significance does
not allow definitive conclusions. Among symptomatic patients,
pain was reduced in 3 (13.6%) with a decrease in analgesic use.
The median duration of palliative response was 7 weeks.
The regimen was generally well tolerated, and no unexpected
toxic effect was observed (Table 3). No grade 4 toxicity was
observed.
The most frequent side effects were neutropenia in 7 (26.9%)
patients and nausea/vomiting in 3 (11.5%) which were grade 1 or
2 in most cases. Grade 3 neutropenia and thrombocytopenia
occurred in 1 patient respectively. A dose reduction of vinorelbine
(30mg) was needed for these 2 patients. At the time of the
analysis, 4 patients (15.4%) were still alive.4. Discussion
The results of this study suggest that lowweekly vinorelbine has a
poor efficacy in heavily pre-treated CRPC suggesting no further
role for this agent in this setting of disease.
The semisynthetic vinca alkaloid with cytotoxic effect
“vinorelbine”, a microtubule-binding agent, is currently avail-
able as an oral formulation has produce interesting results, bothTable 3
Number of patients experiencing the most frequent treatment-
related adverse events.
Grade 2 Grade 3
Neutropenia 7 (26.9%) 1 (3.8%)
Anemia 2 (7.7%) 0
Trombocytopenia 2 (7.7%) 1 (3.8%)
Nausea/vomiting 3 (11.5%) 0
Abdominal pain 1 (3.8%) 0
Diarrhea 1 (3.8%) 0
3as a monotherapy or in combination for several solid tumors
including breast cancer and small cell lung cancer.[14–16] In regard
of prostate cancer, the use of vinorelbine as a monotherapy has
been shown to be effective demonstrating a clinical response rate
and pain control.[6,7,17,18] Specifically, clinical response was
reported to range between 20% and 40%with 20% reduction of
PSA levels.[6,7,17,18] In addition, the oral route of administration
has suggested as a valid option the use of a metronomic oral
vinorelbine.[19]
Over the past years, the new agents abiraterone acetate,
enzalutamide, and cabazitaxel were approved for the treatment
of advanced CRPC. However, the optimal sequencing of these
new drugs remains unclear.[20–23] Unfortunately, there is a
shortage of data on the efficacy of a further line of treatment in
heavily pre-treated CRPC. In 2014, Buonerba et al investigated in
a small study the combination chemotherapy with carboplatin
plus etoposide in a population of patients who progressed after
several therapeutic drugs for CRPC: 2 out of 7 patients with
measurable disease had a partial response, median PFS was 11
weeks (range: 8–18), and median OS was 18 weeks (range: 12–
26).[3] In addition, another small study suggested that low dose
Estramustine phosphate with concomitant low dose acetylsali-
cylic acid is a safe treatment option with some activity for patients
with advanced CRPC who have been heavily pretreated. Thirty-
one patients were enrolled. A total of 9 patients (29.0%) gained a
PSA response. Median PFS was 3.6 months and median OS 7.6
months.[4] Finally, another small study reported a decrease in
PSA levels ≥50% in 7 patients (26.9%); a median PFS of 4.4
months and median OS of 10.7 months for the combination of
weekly docetaxel combined with weekly epirubicin in patients
with advanced CRPC previously exposed to docetaxel and
abiraterone acetate.[5]
In contest, there is an advantage of an oral route of
administration offered by oral vinorelbine in a group of frail
CRPC patients such as those heavily pre-treated of the our study,
unfortunately we have demonstrated a very poor efficacy of
vinorelbine with a decrease in PSA levels ≥50% observed in 2
patients (7.7%); a median PFS of 9 weeks and median OS of 17
weeks. However, we have to report that this study has enrolled a
very poor prognostic group of patients compared with the
aforementioned (Table 4). One of the most interesting data is that
in 9 patients previously exposed to cabazitaxel, only one (11.1%)
achieved a PSA response but in the subgroup of patients who
received previous enzalutamide, 4 (22.2%) out of 18 patients
achieved a PSA response. Although the small number of involved
patients do not allow definitive conclusions this last data may
require further investigation and seems reflect the trend of
successful use of chemotherapy in heavily pre-treated patients not
exposed to previous cabazitaxel.[5] Finally, as expected, we
observed a good safety profile with no grade 4 toxicity or
discontinuation of therapy. However, it is noteworthy that there
are several limitations in our study: first, the small numbers of
patients precluding possible definitive conclusions. Second, the
PFS is a mixed endpoint that includes PSA progression, clinical
progression and disease progression and caution therefore may
be taken before drawing firm conclusions and finally the absence
of a comparison or placebo.
In conclusion, as we all await additional studies which may
clarify the optimal sequencing of the new available agents in
advanced CRPC, the present analysis seems to not suggest the
use of oral vinorelbine on a weekly schedule, in CRPC heavily
pre-treated.
Table 4
Previous studies with chemotherapy in heavily pretreated CRPC.
Study Agent
Number of
patients
Previous Systemic
Therapies For CRPC (%)
50% PSA Response
(%)/Pain Response (%)
Median PFS (months)/
Median OS (months)
Buonerba et al [3] Carboplatin+ etoposide 15 Docetaxel: 100
Abiraterone acetate: 86.7
Enzalutamide: 13.3
Cabazitaxel: 100
Other: 0
6.7/
33.3
∗
2.75/
∗
4.5
Petrioli et al [4] Estramustine posphate 31 Docetaxel:100
Abiraterone acetate: 100
Enzalutamide: 0
Cabazitaxel: 51.6
Other: 48.4
29/
38.7
3.6/
7.4
Petrioli et al [5] Docetaxel+Epirubicin 26 Docetaxel: 100
Abiraterone acetate: 100
Enzalutamide: 0
Cabazitaxel: 15.4
Other: 0
26.9/
38.1
4.4/
10.7
Roviello et al Vinorelbine x os 26 Docetaxel: 100
Abiraterone acetate: 100
Enzalutamide: 69.2
Cabazitaxel: 34.6
Other: 50
7.7/
13.6
∗
2.25/
∗
4.25
∗
Reported as weeks.
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